Reviva announces positive Phase 3 RECOVER trial results for brilaroxazine in schizophrenia

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Primary endpoint met: brilaroxazine 50 mg showed 10.1-point PANSS reduction vs placebo (p<0.001) at week 4.
Statistically significant improvements in all major symptom domains and secondary endpoints at 50 mg dose.
Well-tolerated with no drug-related SAEs; discontinuation rates lower than placebo (16% vs 22%).
Plans to report OLE topline data in Q4 2024 and initiate Phase 3 RECOVER-2 in Q1 2024; NDA submission expected 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.